Glucocorticoids, 11␤-hydroxysteroid dehydrogenase, and fetal
of hypertension, hyperlipidemia, insulin resistance, type programming. Epidemiological studies in many distinct human 2 diabetes, and ischemic heart disease deaths in adult populations have associated low weight or thinness at birth with life [1-13]. Classic adult lifestyle risk factors (smoking, a substantially increased risk of cardiovascular and metabolic alcohol, obesity, social class) appear to be additive to disorders, including hypertension and insulin resistance/type 2 these early life effects [3] . Importantly, the relationships diabetes, in adult life. The concept of fetal "programming" has been advanced to explain this phenomenon. Prenatal glucocorrepresent birthweights within the normal range, rather ticoid therapy reduces birthweight, and steroids are known to than severe intrauterine growth retardation, multiple baexert long-term organizational effects during specific "winbies, or very premature babies. Indeed, the smaller of dows" of development. Therefore, we hypothesized that fetal twins at birth apparently has the higher blood pressure overexposure to endogenous glucocorticoids might underpin the link between early life events and later disease. In rats, in later life [14] . Postnatal "catch-up" growth is also a birthweight is reduced following prenatal exposure to the synrisk factor for subsequent hypertension, ischemic heart thetic glucocorticoid dexamethasone, which readily crosses the disease, and insulin resistance [3, 9, 14, 15] , perhaps sugplacenta, or to carbenoxolone, which inhibits 11␤-hydroxystegesting that smallness at birth due to environmental inroid dehydrogenase type 2 (11␤-HSD2), the physiological fetofluences restraining intrauterine growth are of imporplacental "barrier" to endogenous glucocorticoids. Although the offspring regain the weight deficit by weaning, as adults they tance. The "early life" associations appear also to be exhibit permanent hypertension, hyperglycemia, and increased important predictors of later disease. In Preston, a small hypothalamic-pituitary-adrenal axis activity. Moreover, physibaby with a large placenta had a relative risk of adult ological variations in placental 11␤-HSD2 activity near term hypertension three times that of a large baby with a correlate directly with fetal weight. In humans, 11␤-HSD2 gene mutations produce a low birthweight, and some studies show normal placenta [16] . In 22,000 American men, babies reduced placental 11␤-HSD2 activity in association with intraborn lighter than 5.5 pounds had a relative risk of adult uterine growth retardation. Moreover, low birthweight babies hypertension of 1.26 and of type 2 diabetes of 1.75 comhave higher plasma cortisol levels throughout adult life, indicatpared with babies of average birthweight. Similarly, the ing that hypothalamic-pituitary-adrenal axis programming also relative risk of hypertension in light normal babies was occurs in humans. The molecular mechanisms of glucocorticoid programming are beginning to be unraveled and involve per-1.43 in 71,000 female U.S. nurses [5, 6] . manent and tissue-specific changes in the expression of key genes, notably of the glucocorticoid receptor itself. Thus, glucocorticoid programming may explain, in part, the association PROGRAMMING between fetal events and subsequent disorders in adult life.
To explain these findings, the concept of early life physiological "programming" has been proposed [3, 17, 18]. Such programming has been shown in a variety of Extensive epidemiological studies suggest that factors experimental model systems and reflects the action of a operating in early life are important determinants of the factor during a sensitive period or "window" of developrisk of common and interassociated cardiovascular and ment to exert organizational effects that persist through metabolic disorders of adult life. Data from several dislife. Perinatally, programming factors might produce adtinct populations in the Europe, Asia, Australia, and aptations that optimize survival under conditions of North America have shown that low birthweight or thinstress or deprivation; such responses might be detrimenness at birth strongly predicts the subsequent occurrence tal when the adult environment is not as adverse as "anticipated." Of course, genetic and epigenetic factors that restrain fetal growth and produce later disease may also explain these phenomena, and indeed, loci linked to both low birthweight and adult disorders have been reported [19, 20] . However, the data suggest that envi-GLUCOCORTICOID PROGRAMMING ronmental effects occur, and these have been the main Crucially, prenatal glucocorticoid exposure produces focus of mechanistic research.
permanently elevated offspring blood pressure levels in A major environmental factor advocated in explanation later life. Treatment of pregnant rats with modest doses of fetal programming is maternal malnutrition. Indeed, of dexamethasone, a synthetic glucocorticoid used in dietary restriction during pregnancy in rats, particularly obstetric practice, reduces birthweight and elevates of protein, produces some reduction in birthweight and blood pressure in the adult offspring [49] . Even shortpermanent hypertension and hyperglycemia in the adult term glucocorticoid exposure in the last trimester inoffspring [21-24], effects amplified by later obesity. Howcreases blood pressure in adult life in rats [50] . These ever, the mechanisms that mediate the effects of matereffects are not related to persisting differences in offnal undernutrition on later disease in the offspring are spring weight, which normalizes by weaning. Last-trimesnot fully understood, and any relevance in modern huter administration of dexamethasone also "programs" man populations is moot [25] . Even studies of people born permanent hyperglycemia and, particularly, hyperinsuduring the extreme starvation of the siege of Leningrad linemia in the adult offspring [51] . In contrast, earlier prenatal or postnatal exposure to dexamethasone, while in World War II do not support any strong association reducing fetal or infant growth, has no persisting effects between maternal nutrition and offspring disorders [26] .
on glucose homeostasis in adult life.
GLUCOCORTICOIDS AND PROGRAMMING PHYSIOLOGICAL GLUCOCORTICOIDS AND
Long-term organizational effects are typically found PLACENTAL 11␤-HYDROXYSTEROID with hormones, particularly steroids. An example is the DEHYDROGENASE TYPE 2 action of androgens, which neonatally program the ex-Although glucocorticoids are highly lipophilic and rappression hepatic steroid-metabolizing enzymes, the deidly cross the placenta, normally the fetus has much lower velopment of sexually dimorphic structures in the brain levels of physiological glucocorticoids than its mother and of sexual behavior [27, 28] . These effects can only [52, 53] . This is achieved by placental 11␤-hydroxysteroid be exerted during a specific perinatal period, but then dehydrogenase type 2 (11␤-HSD2), which catalyzes the persist throughout life, largely irrespective of any subserapid metabolism of cortisol and corticosterone to inert quent sex steroid manipulations.
11-keto forms (cortisone, 11-dehydrocorticosterone) Physiological glucocorticoids (cortisol in humans, corti- [54, 55] . This placental enzymic barrier ensures that most, costerone in rats and mice) are synthesized in the adrenal but not all [56] , maternal cortisol is inactivated so that cortex. Several features of fetal glucocorticoid overexpothe majority of cortisol in the human fetal circulation at sure suggest a plausible role in the early life programming term is derived from the fetal adrenals. Dexamethasone, of adult cardiovascular and metabolic disorders. a poor substrate for 11␤-HSD2, crosses the placenta Exogenous glucocorticoids retard fetal growth in hureadily. The efficiency of placental 11␤-HSD2 near term mans and experimental animals, including nonhuman varies considerably in both rats and humans [49, 57] . It primates [18, 29-32]. In humans, fetal cortisol levels are has therefore been hypothesized that relative deficiency increased in intrauterine growth retardation, whether of placental 11␤-HSD2, by allowing increased access of idiopathic or caused by pre-eclampsia [33, 34] . maternal glucocorticoids to the fetus, may retard growth Prenatal glucocorticoids alter the rate of maturation and program responses leading to later disease ( Fig. 1 11␤-HSD2 function at term [60] . Mechanistic studies in Glucocorticoids increase blood pressure and blood pregnant rats with the 11␤-HSD carbenoxolone have glucose levels in adults [46] . Cortisol also elevates fetal shown similar effects to dexamethasone, with reduced blood pressure when infused directly in utero in sheep birthweight and hypertension and hyperglycemia in the adult offspring ( oxolone are apparently independent of changes in mater-nancy selectively attenuates 11␤-HSD2, but not other enzymes in the placenta [63] , and leads to hypertension, nal blood pressure or electrolytes, but require maternal glucocorticoids (that is, they are not seen in the offspring hyperglycemia, and so forth. Thus, glucocorticoid exposure may be one of a limited series of common mecha-of adrenalectomized pregnant rats given carbenoxolone). Intriguingly, dietary protein restriction during rat preg-nisms linking maternal environmental factors with fetal growth and programming. Indeed, in the maternal pro-corticosterone, suggesting the increased hepatic GR expression is of functional importance [51] . Of course, this tein restriction model, offspring hypertension can be prevented by giving the pregnant dam (and her offspring) begs the question of what happens to plasma corticosterone levels in such models. glucocorticoid synthesis inhibitors, and can be recreated by concurrent "replacement" of corticosterone, at least Prenatal dexamethasone permanently attenuates GR (and mineralocorticoid receptor) gene expression in the in female offspring [64] . A note of caution is necessary, however, since 11␤-HSD2 null mice have a normal adult rat hippocampus, a key region responsible for mediating glucocorticoid negative feedback on the HPA birthweight [65]. However, in mice, there is early "shutoff" of 11␤-HSD-2 gene expression in the placenta dur-axis. This may well underpin the documented increases in basal plasma corticosterone levels in adulthood by ing midgestation [66], whereas birthweight predominantly reflects growth late in gestation. Thus, in this reducing sensitivity to glucocorticoid feedback [50] . Of course, elevated glucocorticoid levels might contribute species, the "barrier" may not exist during the phase of maximal growth. In contrast, the activity of 11␤-HSD2 directly to hypertension and hyperglycemia [49] . The reader will have noted that GR transcript levels are ele-in rat placenta is maintained until later in gestation [49] , and in many other mammals, including humans, placenvated in the liver, but reduced in the hippocampus in the tal 11␤-HSD2 activity is fully maintained or even inprenatal dexamethasone model. The molecular mechacreases toward term [57, 67] . Thus, there are clear species nisms are under current study, but may reflect differendifferences in the ontogeny of 11␤-HSD-2 expression in tial promoter usage by the GR gene in each tissue. the placenta, hindering the confidence in extrapolating Crucially, the rat models have allowed further predicdata from results with 11␤-HSD inhibition/disruption in tions to be made in humans. Indeed, low birthweight also rodent species (particularly the mouse) to humans.
correlates with increased adult cortisol levels in humans [74] . Thus, the prenatal glucocorticoid exposure models Sites of glucocorticoid action have reproduced and indeed extended our understand-Glucocorticoids or 11␤-HSD inhibitors administered ing of the fetal origins phenomena. Whether glucocortiduring pregnancy might affect the fetus, the placenta, coids and feto-placental 11␤-HSD2 deficiency are comand/or the mother. Each is plausible [reviewed in 18], mon or exceptional mechanisms of fetal programming in although direct feto-placental effects seem most likely humans remains a key question for future investigation. [61, 62] . Nevertheless, maternal hypertension is linked to fetal high blood pressure and hyperglycemia [68, 69] .
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